Testing effectiveness (Phase 2)Ended earlyNCT01523171
What this trial is testing
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 97